Plain-English translation of NCT07061145 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are studying whether tyrosine kinase inhibitors — medications used to treat chronic myeloid leukemia — may cause or contribute to erectile dysfunction in men. This is an observational study, meaning researchers will collect information from your medical records and follow you over time, without adding any new tests or procedures beyond your regular cancer care. The goal is to understand how often this side effect happens and whether it may be reversible if you stop taking the medication.
Men taking this medication for leukemia sometimes report sexual dysfunction, but doctors don't yet know how common this problem is, which specific medications carry the highest risk, or whether it goes away if treatment is stopped. This study will help answer those questions so patients and doctors can make more informed decisions about treatment.
You likely qualify if…
You likely don't qualify if…
You will allow researchers to review your medical records from when you started treatment (looking back at your health history) and then participate in follow-up monitoring for 24 months going forward. During this time, researchers will track whether sexual dysfunction develops, check your heart health, and monitor your leukemia response — all as part of your regular clinical care, with no additional invasive procedures required. If you eventually stop taking the medication, the study will also track whether any sexual dysfunction improves or resolves.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
Italy